The Sapien 3 Ultra transcatheter aortic heart valve replacement will help improve Edwards Lifesciences Corp. competitive position in the European TAVR market, the company says. But it won't be a factor, at least for the time being, in the largest EU device market, Germany.
The next-gen TAVR device gained a CE mark, Edwards announced Nov. 16. The company is now initiating a "controlled rollout"...





